Certara, Inc. (NASDAQ:CERT – Get Free Report) has been given an average recommendation of “Hold” by the nine research firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $17.79.
Several equities analysts have recently weighed in on CERT shares. UBS Group lowered their price target on Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Robert W. Baird dropped their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. KeyCorp cut their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Barclays dropped their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Finally, JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th.
Read Our Latest Research Report on CERT
Institutional Trading of Certara
Certara Price Performance
Shares of NASDAQ:CERT opened at $11.80 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -30.26, a price-to-earnings-growth ratio of 5.71 and a beta of 1.52. The business has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $15.94. Certara has a fifty-two week low of $11.65 and a fifty-two week high of $19.87.
Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. On average, analysts expect that Certara will post 0.28 earnings per share for the current year.
Certara Company Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
- Five stocks we like better than Certara
- How to Find Undervalued Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- How to Most Effectively Use the MarketBeat Earnings Screener
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.